AR034249A1 - Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones - Google Patents

Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones

Info

Publication number: AR034249A1
Authority: AR; Argentina
Prior art keywords: alkyl; mono; alkoxy; halogen; alkylamino
Prior art date: 2000-03-01

Application number

ARP010100993A

Other languages

English (en)

Spanish (es)

Original Assignee

Orion Corp

Juvantia Pharma Ltd Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-01

Filing date

2001-03-01

Publication date

2004-02-18

2001-03-01 Application filed by Orion Corp, Juvantia Pharma Ltd Oy filed Critical Orion Corp

2004-02-18 Publication of AR034249A1 publication Critical patent/AR034249A1/es

Links

SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract 5
150000001875 compounds Chemical class 0.000 title abstract 3
239000005557 antagonist Substances 0.000 title 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
229910052736 halogen Inorganic materials 0.000 abstract 10
150000002367 halogens Chemical class 0.000 abstract 10
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
125000001424 substituent group Chemical group 0.000 abstract 7
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 6
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 5
-1 C1-6-S- alkyl Chemical group 0.000 abstract 5
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 5
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 5
125000000217 alkyl group Chemical group 0.000 abstract 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
125000001624 naphthyl group Chemical group 0.000 abstract 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 3
229910052757 nitrogen Inorganic materials 0.000 abstract 3
125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

ARP010100993A 2000-03-01 2001-03-01 Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones AR034249A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FI20000480A FI20000480A0 (fi)	2000-03-01	2000-03-01	Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina

Publications (1)

Publication Number	Publication Date
AR034249A1 true AR034249A1 (es)	2004-02-18

Family

ID=8557801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP010100993A AR034249A1 (es)	2000-03-01	2001-03-01	Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones

Country Status (21)

Country	Link
EP (1)	EP1263733A2 (de)
JP (1)	JP2003525274A (de)
KR (1)	KR20020089372A (de)
CN (1)	CN1468224A (de)
AR (1)	AR034249A1 (de)
AU (1)	AU2001239331A1 (de)
BR (1)	BR0108816A (de)
CA (1)	CA2400657A1 (de)
CZ (1)	CZ20022880A3 (de)
EE (1)	EE200200490A (de)
FI (1)	FI20000480A0 (de)
HU (1)	HUP0204458A3 (de)
IL (1)	IL151093A0 (de)
MX (1)	MXPA02008402A (de)
NO (1)	NO20024159L (de)
PE (1)	PE20011084A1 (de)
PL (1)	PL357874A1 (de)
RU (1)	RU2002125944A (de)
SK (1)	SK12332002A3 (de)
WO (1)	WO2001064645A2 (de)
ZA (1)	ZA200206956B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2361869C2 (ru) *	2002-02-05	2009-07-20	ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Новые арил- и гетероарилпиперазины
EP1474401A2 (de) *	2002-02-05	2004-11-10	Novo Nordisk A/S	Neue aryl- und heteroarylpiperazine
HRP20041026A2 (en)	2002-04-03	2005-06-30	Orion Corporation	Polycyclic compounds as potent alpha2-adrenoceptor antagonists
ATE521593T1 (de) *	2002-04-03	2011-09-15	Orion Corp	Verwendung eines alfa2-adrenorezeptorantagonisten bei mit dem zns zusammenhängenden erkrankungen
JP2005536462A (ja) *	2002-04-30	2005-12-02	ユンジンファーマスーチカルインダストリーズカンパニーリミテッド	カスパーゼ−３阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物
WO2004067513A1 (en) *	2003-01-27	2004-08-12	Oy Juvantia Pharma Ltd	Antagonists for alpha-2 adrenoceptors
MX2007015675A (es)	2005-07-04	2008-02-20	Novo Nordisk As	Antagonistas del receptor de histamina h3.
WO2007053436A1 (en)	2005-10-31	2007-05-10	Janssen Pharmaceutica N.V.	Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
CA2636929A1 (en) *	2005-12-21	2007-07-12	Decode Genetics, Ehf	Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
WO2007135131A1 (en) *	2006-05-22	2007-11-29	Janssen Pharmaceutica N.V.	Substituted pyrazinone derivatives for use as a medicine
EP2038256A1 (de)	2006-05-23	2009-03-25	TransTech Pharma, Inc	6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridin und seine verwendung als arzneimittel
EP2402324A1 (de)	2006-05-29	2012-01-04	High Point Pharmaceuticals, LLC	Benzodioxolylcyclopropylpiperazinylpyridazine
EP2014656A3 (de)	2007-06-11	2011-08-24	High Point Pharmaceuticals, LLC	Neue heterocyclische H3-Antagonisten
TWI457122B (zh)	2007-07-20	2014-10-21	Orion Corp	作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
US8324213B2 (en)	2008-10-07	2012-12-04	Merck Sharp & Dohme Corp.	Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators
TW201024282A (en)	2008-11-20	2010-07-01	Orion Corp	New pharmaceutical compounds
US8901129B2 (en)	2009-12-11	2014-12-02	Genecode As	Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
CN103524413B (zh) *	2012-07-04	2016-04-20	江苏先声药物研究有限公司	氢化吖啶衍生物及其应用
CR20160276A (es) *	2013-12-19	2016-10-20	Bayer Pharma AG	"piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c"
CA2944462A1 (en)	2014-03-31	2015-10-08	MiRx Pharmaceuticals, LLC	Novel hdmx inhibitors and their use for cancer treatment
WO2016135137A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
CN107337641B (zh) *	2017-07-01	2020-04-28	广东医科大学	一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
JP2024536926A (ja) *	2021-09-07	2024-10-08	ギズモセラピューティクスインコーポレイテッド	グリコサミノグリカンとのアミロイドペプチド相互作用の阻害剤を含む化合物及び医薬組成物、治療の方法、並びにその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds

2000
- 2000-03-01 FI FI20000480A patent/FI20000480A0/fi unknown
2001
- 2001-02-28 SK SK1233-2002A patent/SK12332002A3/sk unknown
- 2001-02-28 CZ CZ20022880A patent/CZ20022880A3/cs unknown
- 2001-02-28 CA CA002400657A patent/CA2400657A1/en not_active Abandoned
- 2001-02-28 KR KR1020027011453A patent/KR20020089372A/ko not_active Withdrawn
- 2001-02-28 BR BR0108816-5A patent/BR0108816A/pt not_active Application Discontinuation
- 2001-02-28 JP JP2001563488A patent/JP2003525274A/ja active Pending
- 2001-02-28 AU AU2001239331A patent/AU2001239331A1/en not_active Abandoned
- 2001-02-28 RU RU2002125944/04A patent/RU2002125944A/ru not_active Application Discontinuation
- 2001-02-28 EP EP01913918A patent/EP1263733A2/de not_active Withdrawn
- 2001-02-28 IL IL15109301A patent/IL151093A0/xx unknown
- 2001-02-28 HU HU0204458A patent/HUP0204458A3/hu unknown
- 2001-02-28 EE EEP200200490A patent/EE200200490A/xx unknown
- 2001-02-28 CN CNA018059236A patent/CN1468224A/zh active Pending
- 2001-02-28 PL PL01357874A patent/PL357874A1/xx not_active Application Discontinuation
- 2001-02-28 MX MXPA02008402A patent/MXPA02008402A/es unknown
- 2001-02-28 WO PCT/FI2001/000203 patent/WO2001064645A2/en not_active Ceased
- 2001-03-01 AR ARP010100993A patent/AR034249A1/es unknown
- 2001-03-01 PE PE2001000208A patent/PE20011084A1/es not_active Application Discontinuation
2002
- 2002-08-29 ZA ZA200206956A patent/ZA200206956B/en unknown
- 2002-08-30 NO NO20024159A patent/NO20024159L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20020089372A (ko)	2002-11-29
NO20024159D0 (no)	2002-08-30
SK12332002A3 (sk)	2003-07-01
EE200200490A (et)	2003-12-15
PL357874A1 (en)	2004-07-26
NO20024159L (no)	2002-08-30
WO2001064645A3 (en)	2001-12-27
WO2001064645A2 (en)	2001-09-07
HUP0204458A3 (en)	2004-07-28
CZ20022880A3 (cs)	2003-06-18
JP2003525274A (ja)	2003-08-26
EP1263733A2 (de)	2002-12-11
FI20000480A0 (fi)	2000-03-01
ZA200206956B (en)	2003-12-01
HUP0204458A2 (hu)	2003-04-28
RU2002125944A (ru)	2004-02-27
AU2001239331A1 (en)	2001-09-12
IL151093A0 (en)	2003-04-10
CA2400657A1 (en)	2001-09-07
BR0108816A (pt)	2002-12-10
MXPA02008402A (es)	2003-10-14
CN1468224A (zh)	2004-01-14
PE20011084A1 (es)	2001-10-25

Legal Events

Date	Code	Title	Description
2004-05-21	FB	Suspension of granting procedure

Publication	Publication Date	Title
AR034249A1 (es)	2004-02-18	Uso de derivados de quinolina como antagonistas alfa-2; compuestos derivados de quinolina y sus composiciones
CO2022001853A2 (es)	2022-03-29	Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
HUP0301236A2 (hu)	2003-10-28	Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként
PE20220931A1 (es)	2022-05-31	Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR037489A1 (es)	2004-11-17	Quinolinas sustituidas y proceso para su preparacion
AR061815A1 (es)	2008-09-24	Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR025975A1 (es)	2002-12-26	Compuestos quimicos.
AR060658A1 (es)	2008-07-02	Derivados de diceto-piperazina y piperidina como agentes antivirales
AR062074A1 (es)	2008-10-15	Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
AR052943A1 (es)	2007-04-11	Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20080841A1 (es)	2008-06-14	Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
AR055878A1 (es)	2007-09-12	Derivados de ciclopropanocarboxamida
AR032361A1 (es)	2003-11-05	Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
AR030596A1 (es)	2003-08-27	Derivados de quinolina y quinazolina, un procedimiento para su preparacion, composicion farmaceutica que los comprende, uso de los mismos para la elaboracion de medicamentos
AR082152A1 (es)	2012-11-14	Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR012825A1 (es)	2000-11-22	Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos
AR065531A1 (es)	2009-06-10	Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas.
AR060605A1 (es)	2008-07-02	Derivados de diazepano como antagonistas del receptor ccr2
AR065811A1 (es)	2009-07-01	Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR040626A1 (es)	2005-04-13	Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
CY1116183T1 (el)	2017-02-08	Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
AR060811A1 (es)	2008-07-16	Moduladores de mglur5 v
AR053092A1 (es)	2007-04-25	Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR037907A1 (es)	2004-12-22	Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR031526A1 (es)	2003-09-24	Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.